Medicine and Dentistry
Pulmonary Hypertension
100%
Chimeric Antigen Receptor
75%
Malignant Neoplasm
69%
Immunity
57%
Hospital Mortality
56%
Intensive Care
54%
Sepsis
53%
Bloodstream Infection
52%
Intensive Care Unit
50%
Interstitial Lung Disease
50%
Septic Shock
50%
Cytokine Release Syndrome
46%
Chimeric Antigen Receptor T-Cell
41%
Hematologic Malignancy
37%
Cell Therapy
37%
Deterioration
36%
Oncology
35%
Odds Ratio
33%
Clinician
33%
Effector Cell
31%
Hematopoietic Stem Cell Transplantation
31%
Fluid Balance
28%
Antibiotic Therapy
27%
Toxicity and Intoxication
26%
Emphysema
25%
Gestational Hypertension
25%
Survival Analysis
25%
Chronic Obstructive Pulmonary Disease
25%
Treprostinil
25%
Silo-Filler's Disease
25%
COVID-19
25%
Bone Marrow Transplantation
25%
Interleukin 6
25%
Acute Respiratory Distress Syndrome
25%
Graft Versus Host Reaction
25%
Stenotrophomonas maltophilia
25%
Receptor Blocking Agent
25%
Secondary Infection
25%
Acute Respiratory Failure
25%
Interleukin 6 Receptor
25%
Patient Registry
25%
Immunotherapy
25%
Heart Function
25%
Checklist
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
23%
Adverse Event
18%
Targeted Therapy
17%
Antibiotics
16%
Intensivist
16%
Hypertensive Factor
16%
Keyphrases
Pulmonary Arterial Hypertension
81%
Chimeric Antigen Receptor T Cells (CAR-T)
66%
Hospital Mortality
61%
Cytokine Release Syndrome
59%
Pulmonary Hypertension
58%
Interstitial Lung Disease
53%
Septic Shock
50%
Inhaled Treprostinil
50%
Bloodstream Infection
50%
Critically Ill Patients
47%
Intensive Care Unit
42%
Odds Ratio
41%
Patients with Cancer
40%
Hematological Malignancies
39%
Appropriate Antibiotics
38%
Clinical Deterioration
34%
Chimeric Antigen Receptor T-cell Therapy
33%
Critical Care
31%
Cell-Associated
29%
Fluid Balance
28%
Neurotoxicity
28%
Sepsis
27%
Confidence Interval
27%
Clinical Outcomes
27%
Interleukin-6 Levels
25%
Pulmonary Graft-versus-host Disease
25%
Emphysema
25%
Acute Respiratory Failure
25%
Toxicity Management
25%
Mechanically Ventilated Patients
25%
Interleukin-6 Inhibitors
25%
Hypertensive Disorders of Pregnancy
25%
Tyvaso
25%
Dry Powder Inhaler
25%
Lung Disease
25%
Infection Prediction
25%
COVID-19
25%
Interleukin-6
25%
Secondary Infection
25%
Acute Respiratory Distress Syndrome
25%
Bone Marrow Transplantation
25%
Antibiotic Coverage
25%
Prediction Score
25%
Patient Registry
25%
Clinical Considerations
25%
Selexipag
25%
Cancer Hospital
25%
Immune Therapy
25%
Process of Care
25%
Mixed-methods Study
25%
Pharmacology, Toxicology and Pharmaceutical Science
Treprostinil
75%
Pulmonary Hypertension
60%
Malignant Neoplasm
52%
Chimeric Antigen Receptor
50%
Cytokine Release Syndrome
43%
Hospital Mortality
35%
Toxicity and Intoxication
28%
Disease
28%
Bloodstream Infection
27%
Interstitial Lung Disease
27%
Adverse Event
27%
Interleukin 6 Receptor
25%
Secondary Infection
25%
Coronavirinae
25%
Dry Powder Inhaler
25%
Immunotherapy
25%
Adult Respiratory Distress Syndrome
25%
Interleukin 6
25%
Receptor Blocking Agent
25%
Septic Shock
25%
Selexipag
25%
Macrolide
25%
Survival Rate
25%
Tolerability
25%
Deterioration
25%
Sepsis
25%
Health Care Associated Pneumonia
25%
Antibiotics
16%
Community Acquired Pneumonia
15%
Infection
14%
Hypertensive Factor
12%
Cohort Study
12%
Comorbidity
11%
Placebo
10%
Long Term Survival
10%
Cytokine
10%
Tocilizumab
10%
Monoclonal Antibody
10%
Prostacyclin
9%
Organ Toxicity
9%
Overall Survival
8%
Neurotoxicity
8%
Hemophagocytic Syndrome
8%
Brain Edema
7%
Antibiotic Therapy
6%
Mortality Rate
6%
Cytotoxicity
6%
Infectious Agent
5%
Respiratory Failure
5%
Protein Tyrosine Kinase Inhibitor
5%
